Brii Bio shelves once-promising COVID antibody combo that stood up to variants

By choosing antibodies from the plasma of a wide range of recovered COVID-19 patients, Brii Biosciences hoped to score big with a treatment that would stand up to coronavirus variants.

But the brief commercial run of BRII-196/198, a long-acting combination of amubarvimab and romlusevimab, is over, the company said on Friday. Brii will stop manufacturing the cocktail in China and has pulled its submission for emergency use authorization in the United States.